Plus, news about Evommune, Maruho and Nouscom:
Innate Pharma gives up on Phase 1b trial for cancer drug:
The company was evaluating lacutamab as a monotherapy in KIR3DL2-expressing refractory/relapsing peripheral T cell lymphomaKIR3DL2-expressing refractory/relapsing peripheral T cell lymphoma. Innate said it’s
not planning
to restart recruitment in the trial after a
clinical hold
was put into place for studies assessing the drug in PTCL and cutaneous T cell lymphoma after a patient death was reported in the latter. It cited a lack of “meaningful clinical activity” for lacutamab in the PTCL study evaluating the drug as a monotherapy. It is still being studied in combination with chemo in a Phase 2 trial in PTCL.
— Katherine Lewin